Shuttle Pharmaceuticals Holdings, Inc. (SHPH) 10-Year Financial Performance & Capital Metrics

SHPH • • Industrial / General

HealthcareSpecialty & Generic PharmaSpecialty PharmaceuticalsOncology Therapeutics

AboutShuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.Show more

Revenue $0
EBITDA -$8M -30.7%
Net Income -$9M -38.7%
EPS (Diluted) -885.73 -215931.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -383.84% -241.6%
ROIC -456.38% -33.0%
Debt/Equity 1.65 +517.0%
Interest Coverage -5.66 -149.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 35.1% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Expensive at 21.5x book value
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-16.53%

EPS CAGR

10Y-

5Y-

3Y-

TTM-632.47%

ROCE

10Y Avg-642.16%

5Y Avg-144%

3Y Avg-144%

Latest-261.68%

Peer Comparison

Oncology Therapeutics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
HCMHUTCHMED (China) Limited	2.63B	15.31	69.59	-24.8%	77.53%	37.59%	0.12
SHPHShuttle Pharmaceuticals Holdings, Inc.	2.85M	1.48	-0.00			-7.68%	1.65
BGMSBio Green Med Solution, Inc.	7.01M	1.43	-0.00	-89.76%	-67.15%	-76.65%
SBFMSunshine Biopharma, Inc.	5.99M	1.22	-0.17	44.75%	-17.35%	-24.55%	0.04
RNTXRein Therapeutics Inc.	30.49M	1.16	-0.33			-127.48%
CGEMCullinan Therapeutics, Inc.	629.75M	10.66	-3.43			-48.03%	0.00
ONCBeOne Medicines Ltd.	34.44B	338.29	-55.28	54.96%	1.38%	1.66%	0.32

Profit & Loss

	Dec 2017	Dec 2018	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	18.74K	18K	54.95K	60.83K	5.97K	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-18.74K	-18K	-54.95K	-60.83K	-5.97K	0	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	0.04%	-2.05%	-0.11%	0.9%	1%	-
Operating Expenses+	185.15K	568.63K	454.57K	1.68M	2.34M	5.89M	7.7M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	185.99K	513.06K	347.75K	721.18K	1.29M	2.38M	4.08M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	-836	55.57K	161.77K	1.02M	1.05M	3.52M	3.62M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	-54.95K	-60.83K	0	0	0
Operating Income+	-203.89K	-586.63K	-509.52K	-1.74M	-2.34M	-5.89M	-7.7M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-1.88%	0.13%	-2.42%	-0.34%	-1.51%	-0.31%
EBITDA+	-185.15K	-568.63K	-454.57K	-1.68M	-2.34M	-5.89M	-7.69M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-2.07%	0.2%	-2.7%	-0.39%	-1.52%	-0.31%
D&A (Non-Cash Add-back)	18.74K	18K	54.95K	60.83K	5.97K	6.81K	5.46K
EBIT	-202.71K	-595.22K	-766.1K	-1.1M	-4.33M	-4M	-7.78M
Net Interest Income+	0	0	-39.63K	-50.79K	-670.61K	-2.52M	-1.32M
Interest Income	0	0	0	0	0	79.12K	38.14K
Interest Expense	10.88K	30.92K	39.63K	50.79K	670.61K	2.6M	1.36M
Other Income/Expense	-9.7K	-39.51K	-296.21K	590.86K	-2.65M	-700.34K	-1.45M
Pretax Income+	-213.59K	-626.14K	-805.73K	-1.15M	-5M	-6.59M	-9.14M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-213.59K	-626.14K	-805.73K	-1.15M	-5M	-6.59M	-9.14M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-1.93%	-0.29%	-0.43%	-3.34%	-0.32%	-0.39%
Net Income (Continuing)	-213.59K	-626.14K	-805.73K	-1.15M	-5M	-6.59M	-9.14M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.02	-0.05	-0.07	-0.09	-0.30	-0.41	-885.73
EPS Growth %	-	-1.94%	-0.48%	-0.38%	-2.17%	-0.37%	-2159.32%
EPS (Basic)	-0.02	-0.05	-0.07	-0.09	-0.30	-0.41	-885.73
Diluted Shares Outstanding	13.59M	13.59M	13.59M	13.59M	10.35M	15.91M	10.32M
Basic Shares Outstanding	13.59M	13.59M	13.59M	13.59M	10.35M	15.91M	10.32M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2017	Dec 2018	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	102.46K	613.96K	341.19K	509.62K	8.58M	5.59M	2.21M
Cash & Short-Term Investments	50.71K	352.39K	117.15K	504.75K	8.42M	5.46M	1.92M
Cash Only	50.71K	352.39K	117.15K	504.75K	8.42M	2.58M	1.92M
Short-Term Investments	0	0	0	0	0	2.89M	0
Accounts Receivable	49.21K	3.83K	211.46K	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	250K	0	0	0	14.9K	0
Total Non-Current Assets+	18.84K	7.32K	202.86K	142.03K	75.19K	358.73K	295.37K
Property, Plant & Equipment	18.84K	838	196.38K	135.55K	68.71K	358.73K	295.37K
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	6.48K	6.48K	6.48K	6.48K	0	0
Total Assets+	121.3K	621.27K	544.05K	651.64K	8.65M	5.95M	2.51M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	4.12%	-0.12%	0.2%	12.28%	-0.31%	-0.58%
Total Current Liabilities+	405.65K	593.82K	2.1M	2.22M	975.68K	1.04M	1.53M
Accounts Payable	79.1K	30.73K	516.97K	828.31K	129.25K	283.31K	596.6K
Days Payables Outstanding	1.54K	623.16	3.43K	4.97K	7.9K	-	-
Short-Term Debt	314.38K	400K	686.44K	849.5K	685.47K	596K	874.48K
Deferred Revenue (Current)	0	17.54K	228.39K	0	0	0	0
Other Current Liabilities	12.16K	145.54K	386.31K	94.03K	0	0	0
Current Ratio	0.25x	1.03x	0.16x	0.23x	8.79x	5.37x	1.44x
Quick Ratio	0.25x	1.03x	0.16x	0.23x	8.79x	5.37x	1.44x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	129.38K	62.44K	0	853.73K	263.37K
Long-Term Debt	0	0	0	0	0	135.09K	0
Capital Lease Obligations	0	0	129.38K	62.44K	0	304.13K	238.09K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	414.51K	25.28K
Total Liabilities	405.65K	593.82K	2.23M	2.28M	975.68K	1.9M	1.8M
Total Debt+	314.38K	400K	874.28K	978.88K	748.3K	1.09M	1.17M
Net Debt	263.67K	47.61K	757.13K	474.13K	-7.67M	-1.49M	-746.67K
Debt / Equity	-	14.57x	-	-	0.10x	0.27x	1.65x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-18.74x	-18.97x	-12.86x	-34.32x	-3.50x	-2.27x	-5.66x
Total Equity+	-284.35K	27.46K	-1.69M	-1.63M	7.68M	4.06M	709.15K
Equity Growth %	-	1.1%	-62.56%	0.04%	5.72%	-0.47%	-0.83%
Book Value per Share	-0.02	0.00	-0.12	-0.12	0.74	0.25	0.07
Total Shareholders' Equity	-284.35K	27.46K	-1.69M	-1.63M	7.68M	4.06M	709.15K
Common Stock	450K	179	93	93	136	20	41
Retained Earnings	-1.28M	-1.91M	-4.54M	-5.8M	-8.89M	-25.43M	-34.58M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	16.34K	16.34K	16.34K	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2017	Dec 2018	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-202.71K	-566.69K	-26.83K	-300.34K	-2.67M	-5.58M	-7.33M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-1.8%	0.95%	-10.19%	-7.88%	-1.09%	-0.31%
Net Income	-213.59K	-626.14K	-805.73K	-1.15M	-5M	-6.59M	-9.14M
Depreciation & Amortization	18.74K	18K	54.95K	60.83K	5.97K	6.81K	5.46K
Stock-Based Compensation	0	0	459.59K	910.07K	237.55K	181.96K	259.74K
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	58.51K	63.79K	256.58K	-638.26K	2.55M	602.17K	1.41M
Working Capital Changes	-9.03K	16.65K	7.78K	519.15K	-462.79K	220.63K	138.91K
Change in Receivables	-30.43K	45.38K	164.93K	211.46K	0	-14.9K	14.9K
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	10.58K	-48.37K	-51.13K	311.35K	-370.38K	154.06K	313.3K
Cash from Investing+	0	0	-10.82K	0	0	-2.83M	2.92M
Capital Expenditures	0	0	-10.82K	0	0	-19.05K	0
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	160.62K	868.37K	70.07K	687.93K	10.58M	2.57M	3.76M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	-250K	0	0	-17.36K	-679.44K	-370.95K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-202.71K	-566.69K	-37.65K	-300.34K	-2.67M	-5.6M	-7.33M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-1.8%	0.93%	-6.98%	-7.88%	-1.1%	-0.31%
FCF per Share	-0.01	-0.04	-0.00	-0.02	-0.26	-0.35	-0.71
FCF Conversion (FCF/Net Income)	0.95x	0.91x	0.03x	0.26x	0.53x	0.85x	0.80x
Interest Paid	0	0	1.89K	293	39.2K	164.81K	86.59K
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-2280.52%	-	-	-165.17%	-112.37%	-383.84%
Return on Invested Capital (ROIC)	-	-1617.96%	-	-	-	-343.11%	-456.38%
Debt / Equity	-	14.57x	-	-	0.10x	0.27x	1.65x
Interest Coverage	-18.74x	-18.97x	-12.86x	-34.32x	-3.50x	-2.27x	-5.66x
FCF Conversion	0.95x	0.91x	0.03x	0.26x	0.53x	0.85x	0.80x

Frequently Asked Questions

Growth & Financials

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) grew revenue by 0.0% over the past year. Growth has been modest.

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) reported a net loss of $10.7M for fiscal year 2024.

Dividend & Returns

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has a return on equity (ROE) of -383.8%. Negative ROE indicates the company is unprofitable.

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) had negative free cash flow of $11.2M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener